What is IRD's current stock price?

IRD (Opus Genetics, Inc.) is currently trading at $4.26 with a market cap of $346.7M.

What sector is Opus Genetics, Inc. in?

Opus Genetics, Inc. (IRD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IRD a good stock to buy?

Analysts have a Buy consensus on IRD with a price target of $8.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IRD Opus Genetics, Inc.

Healthcare

$4.26-0.70%ClosedMarket Cap: $346.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-80.76

P/S

28.94

EV/EBITDA

-5.61

DCF Value

$-0.28

FCF Yield

-11.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

49.6%

Operating Margin

-359.1%

Net Margin

-892.4%

ROE

6068.8%

ROA

-160.1%

ROIC

-74.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$2.2M	$-65.5M	$—
Q4 null	$3.9M	$-16.5M	$—
FY null	$14.2M	$-49.6M	$—
Q3 null	$3.1M	$-17.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.67

Target (Median)

$9.00

Target Range

$7.00 - $10.00

2 Strong Buy14 Buy0 Hold0 Sell0 Strong Sell

CitizensMarket Outperform

2026-05-13

WedbushOutperform

2026-03-12

Chardan CapitalBuy

2026-03-12

BTIGBuy

2026-03-02

BTIGBuy

2026-01-28

Trading Activity

Insider Trades

View All

Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See Remarks

SellWed May 20

Zaremba Rabourn Amyofficer: Head of Fin. Quality Assurance

SellMon Apr 27

YERXA BENJAMIN Rdirector, officer: President

SellMon Apr 27

SCHACHLE JOSEPH Kofficer: Chief Operating Officer

SellMon Apr 27

Magrath Georgedirector, officer: Chief Executive Officer

SellMon Apr 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.63

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Peers

INO

TIL